Menu
Close
Global
×

Company News

Home Company News News detail
ImmuneOnco Biopharmaceuticals' IMM2520 project completes first subject dosing
2023-03-23
961
Previous article：ImmuneOnco Biopharmaceuticals IMM47, IMM2520 and IMM2510 invention patents were granted by the State Intellectual Property Office of China
Next article：ImmuneOnco Biopharmaceuticals' IMM47, IMM40H, IMM2520, and IMM2902 projects debut at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Back
Hot recommendation
2025-10-02
Application for Phase III Clinical Trial of IMM2510 for IO-Resistant Non-Small Cell Lung Cancer Submitted to CDE
More
2025-09-17
Application for the Phase III Clinical Trial of IMM0306 for the Treatment of Follicular Lymphoma
More
2025-09-16
Important Milestone | IMM2510 (VEGF×PD-L1) Two Phase III Registration Clinical Trials Have Submitted EOP2 Innovative Therapy Enters Key Stage
More

For more information

Please follow the official wechat public account